|Videos|June 22, 2021

Older Age, Asthma, Black Population Influence County-Level COVID-19 Fatality

An interview with a study author on unique associations between county infrastructures and COVID-19 fatality rates.

New data presented at the American Society of Microbiology (ASM) 2021 World Microbe Forum this week showed county-level factors for heightened risk of COVID-19 mortality included increased rates of asthmatic patients, Black persons, and persons aged ≥65 years old in the community.

The findings—which elucidate how county-level factors including total hospitals, insurance rates, and mobile home population rates were associated with fatalities in the first wave of US COVID-19 outbreaks last year—may help provide unique public health intervention targets prior to future outbreaks.

In an interview with Contagion during ASM 2021 regarding the findings, study author Jess Millar, graduate research assistant at the University of Michigan’s departments of Computational Medicine & Bioinformatics and Epidemiology, discussed their contribution to regional-level research and discussion around health inequality relative to the pandemic.

As she noted, previous research has established social determinants of health involved in the unequal impact of COVID-19 on Black and African-American communities—including structural racism’s effect on their access to financial resources, reliance on public transportation, housing instability, and reliance on low-paying retail jobs.

“Our approach considered several other variables that might help explain the effect, but were either non-signficant—such as household crowding, percentage of households without vehicle, and county land area—or were correlated with percentages of Black and African-Americans—such as percentage of single-parent households and percentage living in poverty—further emphasizing the role of systemic racism in COVID-19 case fatality rate,” Millar said.

Watch Millar’s interview with Contagion above.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.